PD-L1 IHC in NSCLC with a global and methodological perspective

Erik Thunnissen; Adrianus J. de Langen; Egbert F. Smit

doi:10.1016/j.lungcan.2017.09.010

PD-L1 IHC in NSCLC with a global and methodological perspective

Erik Thunnissen^*, Adrianus J. de Langen, Egbert F. Smit

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

Abstract

In summary, the PD-L1 biomarker discussed here highlights the importance of understanding the practice of IHC. This can be used to the patients advantage, with appropriate usage. The currently available literature on PD-L1 IHC from a methodologic point of view has not shown that different assays are comparable. The route of laboratory developed test and commercial test validation is the same: challenging and complex. Executing this process along proper methodologic lines is needed to ensure that patients receive the most accurate and representative test outcomes.

Original language	English
Pages (from-to)	102-105
Number of pages	4
Journal	Lung Cancer
Volume	113
DOIs	https://doi.org/10.1016/j.lungcan.2017.09.010
Publication status	Published - 1 Nov 2017

Access to Document

10.1016/j.lungcan.2017.09.010

Cite this

@article{5464186da3d8434182cac260fef91ee9,

title = "PD-L1 IHC in NSCLC with a global and methodological perspective",

abstract = "In summary, the PD-L1 biomarker discussed here highlights the importance of understanding the practice of IHC. This can be used to the patients advantage, with appropriate usage. The currently available literature on PD-L1 IHC from a methodologic point of view has not shown that different assays are comparable. The route of laboratory developed test and commercial test validation is the same: challenging and complex. Executing this process along proper methodologic lines is needed to ensure that patients receive the most accurate and representative test outcomes.",

keywords = "Immunohistochemistry, Lung cancer, Pathology, PD-L1, Review, Validation",

author = "Erik Thunnissen and {de Langen}, {Adrianus J.} and Smit, {Egbert F.}",

year = "2017",

month = nov,

day = "1",

doi = "10.1016/j.lungcan.2017.09.010",

language = "English",

volume = "113",

pages = "102--105",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - PD-L1 IHC in NSCLC with a global and methodological perspective

AU - Thunnissen, Erik

AU - de Langen, Adrianus J.

AU - Smit, Egbert F.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - In summary, the PD-L1 biomarker discussed here highlights the importance of understanding the practice of IHC. This can be used to the patients advantage, with appropriate usage. The currently available literature on PD-L1 IHC from a methodologic point of view has not shown that different assays are comparable. The route of laboratory developed test and commercial test validation is the same: challenging and complex. Executing this process along proper methodologic lines is needed to ensure that patients receive the most accurate and representative test outcomes.

AB - In summary, the PD-L1 biomarker discussed here highlights the importance of understanding the practice of IHC. This can be used to the patients advantage, with appropriate usage. The currently available literature on PD-L1 IHC from a methodologic point of view has not shown that different assays are comparable. The route of laboratory developed test and commercial test validation is the same: challenging and complex. Executing this process along proper methodologic lines is needed to ensure that patients receive the most accurate and representative test outcomes.

KW - Immunohistochemistry

KW - Lung cancer

KW - Pathology

KW - PD-L1

KW - Review

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=85030165504&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2017.09.010

DO - 10.1016/j.lungcan.2017.09.010

M3 - Review article

C2 - 29110835

AN - SCOPUS:85030165504

SN - 0169-5002

VL - 113

SP - 102

EP - 105

JO - Lung Cancer

JF - Lung Cancer

ER -

PD-L1 IHC in NSCLC with a global and methodological perspective

Abstract

Access to Document

Other files and links

Cite this